Investing in new technology: The PET experience

British Journal of Cancer

Volumn 89, Issue 2, 2003, Pages 224-227

  Bradbury, I ^a   Facey, K ^a   Laking, G ^b   Sharp, P ^c  

^a HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER DIAGNOSIS; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; HODGKIN DISEASE; HUMAN; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; STANDARD;

COST-BENEFIT ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; HEALTH CARE COSTS; HODGKIN DISEASE; HUMANS; NATIONAL HEALTH PROGRAMS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SCOTLAND; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0043123121     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601109     Document Type: Review

References (30)

1. Ades A, Cliffe S (2002) Markov Chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making 22 (4): 359-371
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis Db, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (6769): 503-511
3. Anger H (1958) Scintillation camera. Rev Sci Instrum 29: 27-33
4. Berry D (1995) Statistics: A Bayesian Perspective. London: Duxbury Press
5. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406 (6795): 536-540
6. Boyer MJ, Viney R, Fulham M, King M, McCaughan B, Kenny P, Pollicino C, MacLean J (2001) A randomised trial of conventional staging (CS) with or without positron emission tomography (PET) in patients (Pts) with stage 1 or 2 non-small-cell lung cancer (NSCLC). ASCO Abstract 123, ASCO Virtual Meeting
7. Bradbury I, Bonell E, Boynton J, Cummins E, Facey K, Iqbal K, Laking G, McDonald C, Parpia T, Sharp P, Single A, Walker A (2002) Positron emission tomography (PET) imaging in cancer management. Health Technology Assessment Report 2. Glasgow: Health Technology Board for Scotland
8. Claxton K, Posnett J (1996) An economic approach to clinical trial design and research priority-setting. Health Econ 5: 513-524.
9. Claxton K, Sculpher M, Drummond M (2002) A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 360: 711-715
10. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H (2000) Cost-effectiveness of FDG-PET for the management of potentially operable non-small-cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 27 (11): 1598-1609
11. Ell PJ (2002) The gathering of evidence, evidence based medicine, and Joseph Heller's Catch 22 [editorial]. Nucl Med Commun 23: 605
12. Facey K, Lewis J (1998) Guidelines. In Encylopedia of Biostatistics. Armitage P, Colton T (eds). Chichester: Wiley
13. Fenwick E, Claxton K, Sculpher M, Briggs A (2000) Improving the Efficiency and Relevance of Health Technology Assessment: the Role of Iterative Decision Analytic Modelling. York: University of York, Centre for Health Economics
14. French S, Smith J (1997) The Practice of Bayesian Analysis. London: Arnold
15. Fryback D, Thornbury J (1991) The efficacy of diagnostic imaging. Med Decis Making 11: 88-94
16. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J (1996) Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 37: 1428-1436
17. Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270: 1949-1955
18. Laking G, Price P, Sculpher M (2002a) Assessment of technology of functional imaging in cancer. Eur J Cancer 38: 2194-2199
19. Laking GR, Price PM, Sculpher M (2002b) Cost-effectiveness of research into 18F-fluorodeouyglucose positron emission tomography (FDG-PET)-based therapy selection in non-small-cell lung cancer (NSCLC). ASCO, Poster Presentation 1290, Orlando, Florida, 18-21 May
20. Lassen U (2001) Positron Emission Tomography (PET) with 18-F-Fluorodeoxyglucose (FDG): a Survey of the Literature With Regard to Evidence for Clinical Use in Oncology, Cardiology and Neurology. Copenhagen: Danish Centre for Evaluation and Health Technology Assessment
21. Medical Services Advisory Committee (MSAC) (2001) Positron Emission Tomography. Canberra: MSAC
22. Medicare (2001) Coverage Issues Manual: Diagnostic Services. Baltimore, MD: Medicare
23. Phelps ME (2000) Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97: 9226-9233
24. Phillips CV (2001) The economics of 'more research is needed'. Int J Epidemiol 30: 771-776
25. Reichard E, Evans J (1989) Assessing the value of hydrogeologic information for risk-based remedial action decisions. Water Resour Res 25: 1451-1460
26. Reske SN, Bares R, Bull U, Guhlmann A, Moser E, Wannenmacher MF (1996) Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin. Nuklearmedizin 35: 42-52, [in German]
27. Saunders MP, Valle JW (2002) Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence. Br J Cancer 86: 1667-1669
28. Scott WJ, Shepherd J, Gambhir SS (1998) Cost-effectiveness of FDG-PET for staging non-small-cell lung cancer: a decision analysis. Ann Thorac Surg 66: 1876-1883
29. Scottish Executive Health Department (2001) Cancer in Scotland: action for change: Regional Cancer Advisory Groups (RCAGs). HDL(2001)71, 13 September. Edinburgh: Scottish Executive
30. van Tinteren H, Hoekstra OS, Smit EF, Van den Bergh JHAM, Schreurs AJM, Stallaert RALM, van Velthoven PCM, Comans EFI, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, Teule GJJ, PLUS Study Group (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS randomised trial. Lancet 359: 1388-1392